Outcomes of medical treatment of neurocysticercosis: a study of 65 cases in Cheju Island, Korea (Q57216456)

2

0 references

S H Paek

3

0 references

K S Hong

4

0 references

B K Cho

Neurocysticercosis. Short course of treatment with albendazole

5

0 references

language of work or name

English

0 references

publication date

December 1999

0 references

published in

World Neurosurgery

0 references

volume

52

0 references

issue

6

0 references

page(s)

563-9

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Cysticercosis of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Clinical, radiological and cerebrospinal fluid presentation of neurocysticercosis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Is the course of neurocysticercosis modified by treatment with antihelminthic agents?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Evaluation of enzyme-linked immunosorbent assay in serological diagnosis of human neurocysticercosis using paired samples of serum and cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Neurocysticercosis: neurologic, pathogenic, diagnostic and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Epilepsy due to neurocysticercosis: analysis of 203 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Neurocysticercosis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Seroepidemiological observation of Taenia solium cysticercosis in epileptic patients in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Hydrocephalus in cerebral cysticercosis. Pathogenic and therapeutic considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Medical and surgical treatment in neurocysticercosis a magnetic resonance study of 161 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Effect of anticysticercal treatment on the prognosis of epilepsy in neurocysticercosis: a pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Intra-blood-brain barrier IgG synthesis in cerebral cysticercosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Active neurocysticercosis, parenchymal and extraparenchymal: a study of 38 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Immunodiagnosis of neurocysticercosis. Disappointing performance of serology (enzyme-linked immunosorbent assay) in an unbiased sample of neurological patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

ELISA in the diagnosis of neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Short course of albendazole therapy for neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Praziquantel in the treatment of neurocysticercosis: long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Cerebrospinal fluid immunoglobulins in cysticercosis of the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

The course of seizures after treatment for cerebral cysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021

Neurocysticercosis: a major cause of neurological disease worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2899%2900158-5

7 January 2021